<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03333915</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-290-102</org_study_id>
    <nct_id>NCT03333915</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Pharmacokinetics of BGB-290 in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A China Phase I, Open Label, Multi-Center, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activities of BGB-290 in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety, tolerability and PK profile and treatment
      Effect of BGB-290 in Chinese advanced cancer subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From first dose to within 30 days of last dose of BGB-290</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from 0 to the last measureable concentration (AUClast)</measure>
    <time_frame>From pre-dose to the end of cycle 3 (Cycle 1 and cycle 2 are 21 days, cycle 3 is 42 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>From pre-dose to the end of cycle 3 (Cycle 1 and cycle 2 are 21 days, cycle 3 is 42 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>From pre-dose to the end of cycle 3 (Cycle 1 and cycle 2 are 21 days, cycle 3 is 42 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL/F)</measure>
    <time_frame>From pre-dose to the end of cycle 3 (Cycle 1 and cycle 2 are 21 days, cycle 3 is 42 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/F)</measure>
    <time_frame>From pre-dose to the end of cycle 3 (Cycle 1 and cycle 2 are 21 days, cycle 3 is 42 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>From first dose BGB-290 to first documentation of disease progression, assessed up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>From first dose BGB-290 to first documentation of disease progression, assessed up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>From first dose BGB-290 to first documentation of disease progression, assessed up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From first dose BGB-290 to first documentation of disease progression, assessed up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-290</intervention_name>
    <description>Three dose levels will be evaluated in 20mg, 40mg, 60mg separately.</description>
    <arm_group_label>Phase 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria:

               1. Subjects have voluntarily agreed to participate by giving written informed
                  consent.

               2. Age 18-75 years (including 18 and 75 years) on the day of signing informed
                  consent.

               3. Subjects have advanced or metastasis tumor who have experienced disease
                  progression after at least one-line chemotherapy and meet the following
                  eligibility criteria for the corresponding part of the study:

               1. In Dose Escalation:

                    1. The subjects must have a histologically or cytologically confirmed advanced
                       or metastatic triple negative breast cancer (TNBC), high-grade epithelial,
                       non-mucinous, ovarian cancer, fallopian cancer, or primary peritoneal cancer
                       for which no effective standard therapy is available.

                    2. BRCA1 and BRCA2 mutations are not required but enrichment of this subject
                       population is preferred.

                    3. Subjects must agree to retrospective germline BRCA testing using blood
                       samples

                    4. Archival tumor tissues are strongly recommended to be collected if
                       available.

               2. In Dose Expansion:

                    1. Subjects who have histologically or cytologically confirmed advanced or
                       metastatic cancer as described below, and have progressed after receiving at
                       least one prior chemotherapy regimen in the advanced or metastatic setting
                       could be recruited to one of the two expansion arms

                    2. Arm 1. Subjects with high-grade epithelial, non-mucinous, ovarian cancer,
                       fallopian cancer, or primary peritoneal caner harboring germline BRCA1/2 or
                       somatic BRCA1/2 mutation

                    3. Arm 2. Subjects with triple negative breast cancer harboring germline
                       BRCA1/2 or somatic BRCA1/2 mutation

                    4. Subjects must agree to germline BRCA testing using blood samples for
                       pre-screening or confirmation

                    5. Archival tumor tissues are strongly recommended to be collected if
                       available. For subjects with somatic BRCA1/2 mutation, archival tumor tissue
                       or fresh tumor biopsy is mandatory 4. Subjects must have at least one
                       measurable disease as defined per the RECIST V1.1.

                       5. Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.

                       6. Life expectancy ≥ 12 weeks.

                       7. Subject must have adequate organ function

                       8. Female subjects are eligible to enter and participate in the study if
                       they are of non-childbearing potential or childbearing potential, has a
                       negative serum pregnancy test at screening

                       9. Male subjects are eligible to enter and participate in the study if they
                       are vasectomized or agree to use of contraception during the study treatment
                       period and for at least 180 days after the last dose of the study drug.

          -  Exclusion Criteria:

               1. Subjects who were treated with chemotherapy, biologic therapy, immunotherapy or
                  any investigational therapies, if eligible, must have been completed at least 4
                  weeks or at least 5 half-lives (whichever is shorter, but no less than 3 weeks)
                  before the study drug administration, and all AEs have either returned to
                  baseline or stabilized.

               2. Subjects who have undergone major surgery/surgical therapy for any cause within 4
                  weeks of screening visit. subjects must have recovered from the treatment and
                  have a stable clinical condition before entering this study

               3. Subjects who have undergone radiotherapy for any cause within 4 weeks of
                  screening visit. subjects must have recovered from the treatment and have a
                  stable clinical condition before entering this study .

               4. Untreated leptomeningeal or brain metastasis.

               5. Prior therapies targeting PARP

               6. Inability to swallow oral medications (capsules and tablets) without chewing,
                  breaking, crushing, opening or otherwise altering the product formulation.

               7. Acute myocardial infarction and unstable angina, stroke, or transient ischemic
                  attack; Subjects suffering from below heart disease:

                    1. QTcF &gt;480 msec on screening ECG

                    2. Right bundle branch block + left anterior hemiblock or complete left bundle
                       branch block

                    3. Congenital long QT syndrome or family history of unexpected sudden cardiac
                       death

                    4. History or presence of ventricular tachyarrhythmia

                    5. Clinically significant resting bradycardia (&lt; 50 bpm)

                    6. Obligate use of cardiac pacemaker

                    7. g. Other clinically significant heart disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Miao Li, Medical Director</last_name>
    <phone>+86 10 85679808</phone>
    <phone_ext>6073</phone_ext>
    <email>miao.li@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning Li</last_name>
      <phone>+86 10 87788495</phone>
      <email>cancergcp@163.com</email>
    </contact>
    <investigator>
      <last_name>Binghe Xu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tianping Li</last_name>
      <phone>+86 025-68136360</phone>
      <email>jsphkjltp@163.com</email>
    </contact>
    <investigator>
      <last_name>Yongmei Yin, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

